Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia

The downregulation of the glutamate system may be involved in positive, negative, and cognitive symptoms of schizophrenia. Through enhanced glutamate signaling, the activation of the α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid (AMPA) receptor, an ionotropic glutamate receptor, could be a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Maiko, Kunugi, Akiyoshi, Suzuki, Atsushi, Suzuki, Noriko, Suzuki, Motohisa, Kimura, Haruhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507438/
https://www.ncbi.nlm.nih.gov/pubmed/31086673
http://dx.doi.org/10.1002/prp2.479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507438/
https://www.ncbi.nlm.nih.gov/pubmed/31086673
http://dx.doi.org/10.1002/prp2.479

Ejemplares similares